<SEC-DOCUMENT>0001213809-20-000034.txt : 20201013
<SEC-HEADER>0001213809-20-000034.hdr.sgml : 20201013
<ACCEPTANCE-DATETIME>20201013111648
ACCESSION NUMBER:		0001213809-20-000034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201012
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201013
DATE AS OF CHANGE:		20201013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		201235319

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-kdyadicupdatesmarke.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6246ac11f6be49ebabe30d25bd1cc693_1"></div><div style="min-height:72pt;width:100%;"><div style="margin-top:3pt;"><font><br></font></div></div><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%;">UNITED STATES</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center;margin-bottom:7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:31.858%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.983%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.859%;"></td><td style="width:0.1%;"></td></tr><tr style="height:3pt;"><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">FORM 8-K</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:31.858%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.983%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.859%;"></td><td style="width:0.1%;"></td></tr><tr style="height:3pt;"><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">CURRENT REPORT</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">Pursuant to Section 13 or 15(d) of the</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">Securities Exchange Act of 1934</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Date of Report (date of earliest event reported) &#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration: underline;">October 12, 2020</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:31.858%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.983%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.859%;"></td><td style="width:0.1%;"></td></tr><tr style="height:3pt;"><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:148%;">Dyadic International, Inc.</font></div><div style="text-align:center;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:31.858%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.983%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.859%;"></td><td style="width:0.1%;"></td></tr><tr style="height:3pt;"><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:31.858%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.983%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.859%;"></td><td style="width:0.1%;"></td></tr><tr style="height:42pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">Delaware</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">(State or other jurisdiction of incorporation or organization)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">000-55264</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">(Commission File Number)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">45-0486747</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">(I.R.S. Employer Identification Number)</font></div></td></tr><tr style="height:27pt;"><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140 Intracoastal Pointe Drive, Suite 404<br>Jupiter, FL 33477</font></td></tr><tr style="height:12pt;"><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices and zip code)</font></td></tr><tr style="height:14pt;"><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(561) 743-8333</font></td></tr><tr style="height:12pt;"><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Registrant&#8217;s telephone number, including area code)</font></td></tr><tr style="height:27pt;"><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">N&#47;A</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">&#160;(Former Name or Former Address, if Changed Since Last Report)</font></div></td></tr></table></div><div style="margin-top:15pt;margin-bottom:7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:5.873%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:91.927%;"></td><td style="width:0.1%;"></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr style="height:23pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</font></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company &#9744;</font></td></tr><tr style="height:23pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</font></td></tr></table></div><div style="margin-top:9pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act</font></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.128%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.674%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.898%;"></td><td style="width:0.1%;"></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Title of each class</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Trading Symbol(s)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Name of each exchange on which registered</font></div></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common Stock, par value $0.001 per share</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">DYAI</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The NASDAQ Stock Market LLC</font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:3pt;"><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Item 8.01 Other Events</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On October 12, 2020, Dyadic International, Inc. issued a press release with an update on the progress made in certain of its coronavirus (COVID-19) programs globally.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;">A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:23.098%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.901%;"></td><td style="width:0.1%;"></td></tr><tr style="height:12pt;"><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9.01  Financial Statements and Exhibits</font></td></tr><tr style="height:15pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(d)  Exhibits</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr style="height:14pt;"><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The following exhibit is being furnished herein&#58;</font></td></tr><tr style="height:30pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">Exhibit</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;text-decoration: underline;">Number</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</font></td></tr><tr style="height:5pt;"><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr style="height:15pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="ex-991dyadicupdatemark.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;">Press Release dated as of October 12, 2020</a></font></div></td></tr></table></div><div style="margin-top:5pt;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">SIGNATURE</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">Date&#58; October 12, 2020</font></div><div style="text-align:right;margin-bottom:7pt;"><font><br></font></div><div style="text-align:right;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.262%;"><tr><td style="width:1.0%;"></td><td style="width:20.124%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:77.676%;"></td><td style="width:0.1%;"></td></tr><tr style="height:14pt;"><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dyadic International, Inc.</font></td></tr><tr style="height:14pt;"><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Mark A. Emalfarb</font></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark A. Emalfarb</font></td></tr><tr style="height:14pt;"><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:3pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex-991dyadicupdatemark.htm
<DESCRIPTION>EX-99
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="idcd13075349249c2b74221dab022f38f_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="margin-bottom:0.18pt;"><img alt="image1.jpg" src="image1.jpg" style="height:61px;width:76px;"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:99%;">Dyadic Updates Market on COVID-19 Initiatives</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9632;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.96pt;">C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved</font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9632;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.96pt;">Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators</font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9632;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.96pt;">Record Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g&#47;l in 5 days)</font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9632;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.96pt;">Non-Exclusive Technology Usage Agreement with Epygen Biotech of India</font></div><div><font><br></font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">JUPITER, FL &#47; ACCESSWIRE &#47; October 12, 2020 </font><font style="background-color:rgb(255,255,255, 0.0);color:#201f1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. (&#8220;Dyadic&#8221; or the &#34;Company&#34;) (NASDAQ&#58; DYAI), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today is updating the market on the progress made in certain of its coronavirus (COVID-19) programs globally.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic&#8217;s C1 Rapid Recombinant Protein Manufacturing Platform has demonstrated that it can manufacture monoclonal antibodies (mAbs) more efficiently and faster than currently existing CHO mAb technology, potentially broadening access to this therapeutic treatment.  Dyadic has expressed a SARS-CoV-2 monoclonal antibody in collaboration with a biotech company that is developing antibody cocktails to treat COVID-19 patients.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8220;The recent successful use of monoclonal antibody cocktails for the treatment of COVID-19 has also highlighted important production and supply constraints.  Our C1 platform has the potential to generate 3x to 4x greater quantities of monoclonal antibodies in the same timeframe when compared to the current production methods using CHO cells.  While that is still not yet enough to meet anticipated global demand, it certainly is a significant step in potentially helping to ensure greater access to patients, and at a lower cost,&#8221; said Dyadic CEO, Mark Emalfarb.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic has developed a COVID-19 vaccine antigen from its proprietary and patented C1 cell line that can be produced at three grams per liter (3 g&#47;l) in only five days.  The proprietary C1 expressed receptor binding domain (RBD) of the SARS-CoV-2 spike protein is being used in animal trials by seven different research groups, governmental agencies and biopharma companies (including the Israel Institute for Biological Research (IIBR) and a collaboration of European Union scientists that participated with Dyadic in the ZAPI program).  These parties are testing the C1 expressed RBD vaccine candidate(s) in animal trials on a stand-alone basis as well as testing the C1 RBD with nanoparticles and adjuvants.  The Company currently expects up to ten animal trials to be completed by the end of 2020.  These programs are in addition to the previously announced activities with the Frederick National Laboratory, Jiangsu Hengrui Medicine and other third-party collaborations which are working with Dyadic&#8217;s C1 expression platform to express their own COVID-19 and other vaccine and antibody candidates for a number of animal and human health applications.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Data generated by a number of these third parties confirmed that the C1 expressed RBD has the correct structure resulting in high binding and neutralizing capacity.  Additionally, the recently concluded IIBR mice study shows that the C1 RBD has the potential to generate excellent immunogenicity responses with very high titers and neutralizing antibodies against the SARS-CoV-2 coronavirus.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8220;The initial mice trial, as reported to us by the IIBR, was very successful, and we expect to have additional data to disclose after a number of these animal trials are completed and their data is analyzed further. Going forward, we expect there will be follow-on animal studies which will include challenge studies with hamsters and human Ace2 transgenic mice, as well as additional studies including a toxicology study,&#8221; continued Mr. Emalfarb.  &#8220;Further, our C1 technology can express high levels of proteins more rapidly at flexible commercial scales more affordably using single use or stainless-steel bioreactors.  We believe that our C1 platform, developed initially for high-volume low-cost industrial use, easily enables affordable, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">regional production of vaccines, antibodies and other therapeutic proteins, which has driven a heightened interest in our C1 technology.&#8221;</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic has recently entered into a non-exclusive technology usage agreement with Epygen Biotech of India, who after obtaining required funding, expects to produce cGMP clinical trial material at their facility and conduct clinical trials in India using Dyadic&#8217;s C1 expressed RBD antigen of the SARS-CoV-2 Spike Protein. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8220;The Epygen agreement demonstrates how potential collaborators globally can develop and eventually manufacture vaccines and drugs on a regional basis that are affordable, safe and effective.  Debayan Ghosh, President and Founder of Epygen, is intimately familiar with our technology from his work at Biocon as a biotechnologist, his time spent working for Dyadic in the late 90&#8217;s and, most recently, as a result of  Epygen&#8217;s interest in the manufacturing of cGMP clinical grade C1 expressed RBD antigens.  It is especially gratifying for us to be working with someone who understands, firsthand, C1&#8217;s success in industrial biotech and appreciates how the technology can be broadly applied to biopharmaceuticals,&#8221; concluded Mr. Emalfarb.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">About Dyadic International, Inc. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermothelomyces heterothallica (formerly Myceliophthora thermophila)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and&#47;or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please visit Dyadic&#8217;s website at </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">http&#58;&#47;&#47;www.dyadic.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for additional information, including details regarding Dyadic&#8217;s plans for its biopharmaceutical business.</font></div><div style="margin-bottom:6pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Safe Harbor Regarding Forward-Looking Statements</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International&#8217;s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company&#8217;s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled &#8220;Risk Factors&#8221; in Dyadic&#8217;s annual reports on Form 10-K and quarterly reports on </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic&#8217;s periodic filings with the SEC, which are accessible on the SEC&#8217;s website and at </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">http&#58;&#47;&#47;www.dyadic.com&#47;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contact&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ping W. Rawson</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chief Financial Officer</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Phone&#58; (561) 743-8333</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Email&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">mailto&#58;prawson&#64;dyadic.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
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M[.! Y)ETF&H*0'X0E6F09])@JD"/ZKH2HZ5&+N4%:Y ;3.TUR DF.0.09PI
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M3"7-DN3T?QFPYG$8/<B=TF2+NO$A]!-'J!G!%@*,GGB+K_IRS;G\[6'6R9Q
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&3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
